Keywords IL-17RA colon cancer EMT anti-tumor immunity IL-17 CRC mycobiome immunotherapy inflammation Introduction Colorectal cancer (CRC) remains the third-most prevalent cancer worldwide, with a very poor overall 5-year survival rate of 64%.1 The development of CRC is a prime example of how tumorigenesis spanning all stages, from early tumorigenesis to invasion and metastasis, depends on the close interaction of mutagenized epithelial cells with their tumor microenvironment (TME).2 The TME...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Claire
Contact Claire, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack